Stem Cells and Diabetic Retinopathy

In the field of ophthalmology, diabetic retinopathy (DR) is one of the leading causes of blindness. Despite recent advances in our understanding of the pathogenesis of DR, there is still no cure for this disease. stem cell therapy has emerged as a potential treatment for DR, as stem cells are capable of self-renewal and differentiation into multiple cell types. Mesenchymal stem cells (MSCs) are a type of stem cell that can be derived from various sources, including the bone marrow, adipose tissue, and umbilical cord. MSCs have shown promise in the treatment of a variety of diseases, including DR. In a recent clinical trial, MSCs were injected into the vitreous cavity of patients with DR. The results showed that MSC therapy was safe and effective in improving the symptoms of DR. The mechanisms by which MSCs improve the symptoms of DR are not fully understood. However, it is thought that MSCs exert their therapeutic effects through the secretion of trophic factors and by modulating the immune response. MSCs also have the ability to differentiate into various cell types, including retinal cells. This provides a potential mechanism by which MSCs could replace damaged cells in the retina and improve vision in patients with DR. MSC therapy is a promising new treatment for DR. However, further research is needed to improve our understanding of the mechanisms by which MSCs exert their therapeutic effects and to determine the long-term safety and efficacy of this treatment.

 "Insights into stem cell therapy for diabetic retinopathy - NCBI." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818871/. Accessed 21 Oct. 2022.

 "Adult Stem Cell Therapeutics in Diabetic Retinopathy - PMC - NCBI." 30 Sep. 2019, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801872/. Accessed 21 Oct. 2022.

 "Novel stem cell and gene therapy in diabetic retinopathy, age ...." 13 Feb. 2019, https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0158-y. Accessed 21 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
IV50,000,0003150,000,000
Intrathecal20,000,000120,000,000
Exosome Eye Drops10,000,0001N/A
Total170,000,000